Histone deacetylase inhibitors in Hodgkin lymphoma

Investigational New Drugs

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Buglio, Daniela ^a   Younes, Anas ^a  

^a Box 429 ^*  (United States)

Author keywords

Hodgkin lymphoma; Role of histone deacetylase inhibitors

Indexed keywords

BORTEZOMIB; CANCER TESTIS ANTIGEN; CHLORMETHINE; ENTINOSTAT; GEMCITABINE; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; NY ESO 1 ANTIGEN; PANOBINOSTAT; ROMIDEPSIN; STAT6 PROTEIN; VIRUS ANTIGEN; VORINOSTAT;

ABSENCE OF SIDE EFFECTS; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CELL CYCLE ARREST; CELL PROLIFERATION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EPSTEIN BARR VIRUS; FATIGUE; GENE ACTIVITY; GENETIC EPIGENESIS; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HODGKIN DISEASE; HUMAN; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; REED STERNBERG CELL; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION;

CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HODGKIN DISEASE; HUMANS; RECURRENCE;

EID: 78651378094     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-010-9588-y     Document Type: Article

References (51)

1. PA Jones SB Baylin 2007 The epigenomics of cancer Cell 128 683 692 1:CAS:528:DC%2BD2sXis12ju7k%3D 10.1016/j.cell.2007.01.029 17320506 (Pubitemid 46273572)
2. JP Issa 2007 DNA methylation as a therapeutic target in cancer Clin Cancer Res 13 1634 1637 1:CAS:528:DC%2BD2sXivV2gtr8%3D 10.1158/1078-0432.CCR-06- 2076 17363514 (Pubitemid 46952927)
3. MA Glozak E Seto 2007 Histone deacetylases and cancer Oncogene 26 5420 5432 1:CAS:528:DC%2BD2sXovFeku7Y%3D 10.1038/sj.onc.1210610 17694083 (Pubitemid 47255924)
4. SB Baylin 2005 DNA methylation and gene silencing in cancer Nat Clin Pract Oncol 2 Suppl 1 S4 S11 1:CAS:528:DC%2BD28Xjs1Gisg%3D%3D 10.1038/ncponc0354 16341240 (Pubitemid 43135229)
5. S Marsoni G Damia G Camboni 2008 A work in progress: the clinical development of histone deacetylase inhibitors Epigenetics 3 164 171 10.4161/epi.3.3.6253 18487953
6. U Heider M Kaiser J Sterz, et al. 2006 Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma Eur J Haematol 76 42 50 1:CAS:528:DC%2BD28XitFSlt7c%3D 10.1111/j.1600-0609.2005.00546.x 16343270
7. S Wang Y Yan-Neale R Cai I Alimov D Cohen 2006 Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824 Cell Cycle 5 1662 1668 1:CAS:528:DC%2BD28Xht12ht7rI 10.4161/cc.5.15.3099 16861932
8. JL Brogdon Y Xu SJ Szabo, et al. 2007 Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function Blood 109 1123 1130 1:CAS:528:DC%2BD2sXjtFert7Y%3D 10.1182/blood-2006- 04-019711 17008546 (Pubitemid 46220659)
9. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 769 784 1:CAS:528: DC%2BD28XptVCltrY%3D 10.1038/nrd2133 16955068 (Pubitemid 44348499)
10. S Minucci PG Pelicci 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 38 51 1:CAS:528:DC%2BD28Xht1GgsA%3D%3D 10.1038/nrc1779 16397526 (Pubitemid 43054973)
11. MA Glozak N Sengupta X Zhang E Seto 2005 Acetylation and deacetylation of non-histone proteins Gene 363 15 23 1:CAS:528:DC%2BD2MXht1Klu7%2FN 10.1016/j.gene.2005.09.010 16289629 (Pubitemid 41691888)
12. DS Schrump 2009 Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications Clin Cancer Res 15 3947 3957 1:CAS:528:DC%2BD1MXntlOis74%3D 10.1158/1078-0432.CCR-08-2787 19509170
13. L Stimson V Wood O Khan S Fotheringham NB La Thangue 2009 HDAC inhibitor-based therapies and haematological malignancy Ann Oncol 20 1293 1302 1:STN:280:DC%2BD1MrjtlOkuw%3D%3D 10.1093/annonc/mdn792 19515748
14. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 39 1:CAS:528:DC%2BD2sXivVyrt7g%3D 10.1182/blood-2006-06- 025999 16960145 (Pubitemid 46053039)
15. RL Piekarz R Frye M Turner, et al. 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 5410 5417 1:CAS:528:DC%2BD1MXhsFKkt7vO 10.1200/JCO.2008.21.6150 19826128
16. N Khan M Jeffers S Kumar, et al. 2008 Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem J 409 581 589 1:CAS:528:DC%2BD1cXhtlSru7o%3D 10.1042/BJ20070779 17868033 (Pubitemid 351184977)
17. G Bi G Jiang 2006 The molecular mechanism of HDAC inhibitors in anticancer effects Cell Mol Immunol 3 285 290 1:CAS:528:DC%2BD28XhtFOnurjO 16978537
18. Beumer JH, Tawbi H (2010) Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol 5(3):196-208
19. AA Lane BA Chabner 2009 Histone deacetylase inhibitors in cancer therapy J Clin Oncol 27 5459 5468 1:CAS:528:DC%2BD1MXhsFKkt7vE 10.1200/JCO.2009.22.1291 19826124
20. Borbone E, Berlingieri MT, De Bellis F et al (2010) Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29:105-116
21. HM Prince MJ Bishton SJ Harrison 2009 Clinical studies of histone deacetylase inhibitors Clin Cancer Res 15 3958 3969 1:CAS:528: DC%2BD1MXntlOis78%3D 10.1158/1078-0432.CCR-08-2785 19509172
22. PA Marks WS Xu 2009 Histone deacetylase inhibitors: potential in cancer therapy J Cell Biochem 107 600 608 1:CAS:528:DC%2BD1MXosFOiurg%3D 10.1002/jcb.22185 19459166
23. OA O'Connor ML Heaney L Schwartz, et al. 2006 Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 24 166 173 10.1200/JCO.2005.01.9679 16330674 (Pubitemid 46630509)
24. MH Kirschbaum BH Goldman JM Zain, et al. 2007 Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory hodgkin lymphoma: SWOG 0517 Blood (ASH Annual Meeting Abstracts) 110 2574
25. MH Kirschbaum JM Zain L Popplewell, et al. 2007 A phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent Non Hodgkin Lymphoma. A California Cancer Consortium Study Blood (ASH Annual Meeting Abstracts) 110 2568
26. A Younes B Pro M Fanale, et al. 2007 Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin Lymphoma (HL) Blood (ASH Annual Meeting Abstracts) 110 2566
27. A Younes A Wedgwood P McLaughlin, et al. 2007 Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study Blood (ASH Annual Meeting Abstracts) 110 2571
28. Younes A (2009) Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology 2009:507-519
29. M Dickinson D Ritchie DJ DeAngelo, et al. 2009 Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma Br J Haematol 147 97 101 1:CAS:528: DC%2BD1MXhtlWltbbF 10.1111/j.1365-2141.2009.07837.x 19663825
30. I Schwering A Brauninger U Klein, et al. 2003 Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood 101 1505 1512 1:CAS:528:DC%2BD3sXht1agu7k%3D 10.1182/blood-2002-03-0839 12393731 (Pubitemid 36182527)
31. A Ushmorov O Ritz M Hummel, et al. 2004 Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression Blood 104 3326 3334 1:CAS:528:DC%2BD2cXhtVWhurvP 10.1182/blood-2003-04-1197 15284123 (Pubitemid 39507153)
32. A Ushmorov F Leithauser O Sakk, et al. 2006 Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma Blood 107 2493 2500 1:CAS:528:DC%2BD28XisFOju74%3D 10.1182/blood-2005-09-3765 16304050 (Pubitemid 43345573)
33. NM Khaskhely D Buglio J Shafer CM Bollard A Younes 2009 The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) targets Hodgkin Lymphoma through a dual mechanism of immune modulation and apoptosis induction Blood (ASH Annual Meeting Abstracts) 114 1562
34. D Buglio V Mamidipudi NM Khaskhely, et al. 2009 The histone deacetylase inhibitor MGCD0103 down regulates CD30, activates NF-Kb, and synergizes with proteasome inhibitors by HDAC6 independent mechanism in Hodgkin Lymphoma Blood (ASH Annual Meeting Abstracts) 114 3735
35. D Buglio GV Georgiakis S Hanabuchi, et al. 2008 Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines Blood 112 1424 1433 1:CAS:528:DC%2BD1cXpvVOktb0%3D 10.1182/blood-2008-01-133769 18541724
36. CM Bollard L Aguilar KC Straathof, et al. 2004 Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease J Exp Med 200 1623 1633 1:CAS:528:DC%2BD2cXhtFGmurbI 10.1084/jem.20040890 15611290 (Pubitemid 40094186)
37. CM Bollard S Gottschalk AM Leen, et al. 2007 Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer Blood 110 2838 2845 1:CAS:528:DC%2BD2sXht1SmurfJ 10.1182/blood-2007-05-091280 17609424 (Pubitemid 350006936)
38. BF Israel SC Kenney 2003 Virally targeted therapies for EBV-associated malignancies Oncogene 22 5122 5130 1:CAS:528:DC%2BD3sXmtFahurw%3D 10.1038/sj.onc.1206548 12910249 (Pubitemid 37059593)
39. WH Feng G Hong HJ Delecluse SC Kenney 2004 Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas J Virol 78 1893 1902 1:CAS:528:DC%2BD2cXhtFKnsro%3D 10.1128/JVI.78.4.1893-1902.2004 14747554 (Pubitemid 38176721)
40. WH Feng SC Kenney 2006 Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression Cancer Res 66 8762 8769 1:CAS:528:DC%2BD28XovF2hsLY%3D 10.1158/0008-5472.CAN-06- 1006 16951192 (Pubitemid 44449193)
41. H Chambost N Van Baren F Brasseur, et al. 2000 Expression of gene MAGE-A4 in Reed-Sternberg cells Blood 95 3530 3533 1:CAS:528:DC%2BD3cXjsl2isb0%3D 10828039
42. GW Colleoni P Capodieci S Tickoo J Cossman DA Filippa M Ladanyi 2002 Expression of SSX genes in the neoplastic cells of Hodgkin's lymphoma Hum Pathol 33 496 502 1:CAS:528:DC%2BD38XlslCls7g%3D 10.1053/hupa.2002.124909 12094374 (Pubitemid 34747868)
43. S Shichijo A Yamada K Sagawa, et al. 1996 Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2′-deoxycytidine Jpn J Cancer Res 87 751 756 1:CAS:528:DyaK28Xks1ejtL8%3D 8698626
44. A Gloghini D Buglio NM Khaskhely, et al. 2009 Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors Br J Haematol 147 515 525 1:CAS:528:DC%2BD1MXhsFKjtbzN 10.1111/j.1365-2141.2009.07887.x 19775297
45. D Buglio GV Georgakis S Hanabuchi, et al. 2008 Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines Blood 112 1424 1433 1:CAS:528:DC%2BD1cXpvVOktb0%3D 10.1182/blood-2008-01-133769 18541724
46. M Fournel C Bonfils Y Hou, et al. 2008 MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo Mol Cancer Ther 7 759 768 1:CAS:528: DC%2BD1cXks1Gms70%3D 10.1158/1535-7163.MCT-07-2026 18413790 (Pubitemid 351551029)
47. RE Martell G Garcia-Manero A Younes, et al. 2009 Clinical development of MGCD0103, an isotype-selective HDAC inhibitor: pericarditis/pericardial effusion in the context of overall safety and efficacy Blood (ASH Annual Meeting Abstracts) 114 4756
48. A Younes T-C Ong V Ribrag, et al. 2009 Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin Lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant Blood (ASH Annual Meeting Abstracts) 114 923
49. S Viviani V Bonfante C Fasola P Valagussa AM Gianni 2008 Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients ASCO Meeting Abstracts 26 8532
50. C Carlo-Stella A Guidetti S Viviani, et al. 2008 Phase II trial of combination of the histone deacetylase inhibitor ITF2357 and meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed/refractory Hodgkin Lymphoma (HL) Blood (ASH Annual Meeting Abstracts) 112 2586
51. A Spencer DJ DeAngelo HM Prince, et al. 2008 Oral panobinostat (LBH589), a novel deacetylase inhibitor (DACi) demonstrates clinical activity in relapsed/refractory Hodgkin lymphoma (HL) Ann Oncol 19 136 10.1093/annonc/mdn329 Abstract